After the sale of the remaining state capital, Bosnalijek continued with its successful work and an increase in profits, it was confirmed to Fena from this company.
The largest pharmaceutical company in BiH had net profits of 52 million BAM in the first six months of this year, which is a 13% increase compared to the same period last year.
On the domestic market and the Russian market, which are the two most significant ones for Bosnalijek, the positive trend in profit growth was continued so that the company is marking 16% growth in Russia and 14% growth in BiH. Bosnalijek was able to acquire the Russian GMP certificate, which ensures its ability to export to that large market in the long term.
After the turbulent events in Ukraine in the last two years, which significantly impacted the sale of Bosnalijek’s products on this market, their products are once again being sold there. Continuity and stability have been established once again.
They’re content in Bosnalijek with the realized results in neighboring countries, as well. They’ve grown 9% in Serbia and 8% in Montenegro in the first six months of this year. Significant activities are being undertaken to open other markets for Bosnalijek’s products. The necessary permits are being gathered in order to export to Turkey.
Bosnalijek is continuing investment in expansion and modernization of production so production in the new facility Galenovo will be opened this month, which will also result in additional jobs. Works in the quality control unit are nearing end and should be done by the end of this year.
(Source: Klix.ba)
